The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for oncological treatment-the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small-molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly druggable and attractive target class. Despite the role deregulated kinase activity plays in cancer, only 8% of the kinome has been effectively "drugged." Moreover, 24% of the 634 human kinases are understudied. We have developed a comprehensive scoring system that utilizes differential gene expression, pathological parameters, overall survival, and mutational hotspot analysis to rank and prioritize clinically relevant kinases across 17 solid tumor cancers from The Cancer Genome Atlas. We have developed the clinical kinase index (CKI) app (http://cki.ccs.miami.edu) to facilitate interactive analysis of all kinases in each cancer. Collectively, we report that understudied kinases have potential clinical value as biomarkers or drug targets that warrant further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111 · cited 1×
“The unfolded protein response (UPR) pathway is a pro-survival pathway that is hijacked by cancer cells and thus has been a topic of discussion in the context of drug development.(34) Other understudied kinases that score favorably in the majority of cancer cohorts include PKMYT1 (Tchem), DCLK3 (Tchem), BRSK1 (Tchem),…”
BackgroundDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
On the Dependency of Cellular Protein Levels on mRNA Abundance
Liu, Y., Beyer, A., & Aebersold, R. (2016) · Cell · doi:10.1016/j.cell.2016.03.014 · Cited by 3,221
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Toward a Shared Vision for Cancer Genomic Data
Grossman, R. L., Heath, A. P., Ferretti, V., Varmus, H. E., Lowy, D. R., Kibbe, W. A., & Staudt, L. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607591 · Cited by 1,680
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066 · cited 2×
“The target should not be uniformly distributed and expressed throughout the body, a characteristic that can be checked using expression databases such as GTex69 or The Human Protein Atlas.70 Also, immunoprecipitation (IP) is a critical consideration.”
BackgroundValidating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712 · cited 2×
“The typical 20-year-long, multi-billion-dollar drug discovery pipeline all begins with target identification and prioritization.(66) This is arguably one of the most important steps, as drug failure in the clinic is mostly due to a lack of efficacy or due to toxicities from poor target choice.”
BackgroundThe Genotype-Tissue Expression (GTEx) Project
Carithers, L. J., & Moore, H. M. (2015) · Biopreservation and Biobanking · doi:10.1089/bio.2015.29031.hmm · Cited by 549
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
DrugCentral: online drug compendium
Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw993 · Cited by 323 · cited 1×
“8 Cell Reports Medicine 1, 100128, October 20, 2020 nib, vandetanib, bosutinib, sorafenib, and sunitinib all inhibit understudied kinases in the low nanomolar range (including SBK3, STK32A, RIOK1, CDK15, and CSNK1A1L), one of which is Tdark (CSNK1A1L).(1) Thus, it is possible that some therapeutic effect or anti-cance…”
BackgroundPharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279 · cited 2×
“8% (151) of the 634 kinases are ‘‘understudied,’’ as they lack sufficient GeneRIFs, antibodies, citations in the literature, and potent chemical probes.(11) Consistent with this is the fact that the current kinase inhibitors target not only a narrow range of targets, but also a narrow range of pathways including angio…”
BackgroundSelf-citationZhao, Q., Shi, X., Xie, Y., Huang, J., Shia, B., & Ma, S. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbu003 · Cited by 154
Publisher Correction: Network-based prediction of drug combinations
Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019) · Nature Communications · doi:10.1038/s41467-019-09692-y · Cited by 131
MEK inhibition in non-small cell lung cancer
Stinchcombe, T. E., & Johnson, G. L. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.005 · Cited by 69
Cited by
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Evolutionary and cellular analysis of the ‘dark’ pseudokinase PSKH2
Byrne, D. P., Shrestha, S., Daly, L. A., Marensi, V., Ramakrishnan, K., Eyers, C. E., Kannan, N., & Eyers, P. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220474 · Cited by 5
(2023) · doi:10.1101/2023.02.28.530483 · Cited by 5
Evolutionary and cellular analysis of the dark pseudokinase PSKH2
Byrne, D. P., Shrestha, S., Daly, L. A., Marensi, V., Ramakrishnan, K., Eyers, C. E., Kannan, N., & Eyers, P. A. (2022) · doi:10.1101/2022.09.10.507278 · Cited by 5
AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK
Essegian, D. J., Chavez, V., Khurshid, R., Merchan, J. R., & Schürer, S. C. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010263 · Cited by 4
Self-citation
Metadata
- Authors
- Essegian, D., Khurana, R., Stathias, V., & Schürer, S. C.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 1
- Issue
- 7
- Pages
- 100128
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W3093660856
- Cited by
- 74
- References
- 17
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.